Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesSYNTAX Analysis Finds Treatment With TAXUS Express2 Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease
Boston Scientific, 05/21/09
Boston Scientific Corporation announced results from an analysis of economic and quality of life outcomes, based on one-year data from its landmark SYNTAX trial. The results found that percutaneous coronary intervention using the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System was consistently associated with fewer patient hospital days during the first year after treatment compared to coronary artery bypass graft surgery. Total medical costs at one year were also lower with PCI. Analysis of the data was presented by Ben van Hout, Ph.D., of the University of Utrecht, The Netherlands, at the annual EuroPCR Scientific Program in Barcelona.
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Vernakalant hydrochloride for the treatment of atrial fibrillation
Expert Opinion on Investigational Drugs, 11/30/09
The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences
Vascular Health and Risk Management, 11/30/09
Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category
Metabolic Syndrome and Related Disorders, 11/30/09
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Healthcare Costs and Obesity Prevention: Drug Costs and Other Sector-Specific Consequences
PharmacoEconomics, 11/30/09
Willingness to Pay for a QALY Based on Community Member and Patient Preferences for Temporary Health States Associated with Herpes Zoster
PharmacoEconomics, 11/24/09
Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials
PharmacoEconomics, 11/24/09
Sponsor
Article Search
Sponsor